Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer

New England Journal of Medicine, Journal Year: 2017, Volume and Issue: 377(9), P. 849 - 861

Published: Aug. 30, 2017

Smoking cessation has reduced the incidence of lung cancer. The authors this review discuss recent progress in diagnostic and treatment approaches, including molecular characterization to determine likelihood a response targeted agents immunotherapies.

Language: Английский

---

Emerging trends in the novel drug delivery approaches for the treatment of lung cancer

Chemico-Biological Interactions, Journal Year: 2019, Volume and Issue: 309, P. 108720 - 108720

Published: June 18, 2019

Language: Английский

---

Non‐small cell lung cancer in China

Cancer Communications, Journal Year: 2022, Volume and Issue: 42(10), P. 937 - 970

Published: Sept. 8, 2022

In China, lung cancer is a primary type with high incidence and mortality. Risk factors for include tobacco use, family history, radiation exposure, the presence of chronic diseases. Most early-stage non-small cell (NSCLC) patients miss optimal timing treatment due to lack clinical presentations. Population-based nationwide screening programs are significant help in increasing early detection survival rates NSCLC China. The understanding molecular carcinogenesis identification oncogenic drivers dramatically facilitate development targeted therapy NSCLC, thus prolonging positive drivers. exploration immune escape mechanisms, programmed death protein 1 (PD-1)/programmed death-ligand (PD-L1) inhibitor monotherapy PD-1/PD-L1 plus chemotherapy have become standard care advanced Chinese Society Clinical Oncology's guidelines maintenance immunotherapy recommended locally after chemoradiotherapy. Adjuvant neoadjuvant chemoimmunotherapy will be approved resectable NSCLC. this review, we summarized recent advances China terms epidemiology, biology, pathology, pathogenesis, screening, diagnosis, therapy, immunotherapy.

Language: Английский

---

Fibroblast growth factor receptors as treatment targets in clinical oncology

Nature Reviews Clinical Oncology, Journal Year: 2018, Volume and Issue: 16(2), P. 105 - 122

Published: Oct. 26, 2018

Language: Английский

---

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

The Lancet Oncology, Journal Year: 2017, Volume and Issue: 18(5), P. 599 - 610

Published: April 1, 2017

Language: Английский

---

Molecular epidemiology and diagnostics of KRAS mutations in human cancer

Cancer and Metastasis Reviews, Journal Year: 2020, Volume and Issue: 39(4), P. 1029 - 1038

Published: July 29, 2020

Abstract RAS mutation is the most frequent oncogenic alteration in human cancers. KRAS frequently mutated followed by NRAS. The emblematic mutant cancers are pancreatic, colorectal, lung adenocarcinomas and urogenital frequencies relatively stable worldwide various cancer types with one exception of adenocarcinoma. variant alleles appears type specific, reflecting carcinogenic processes. In addition to point KRAS, allelic imbalances also leading predominance a allele. characterized typical, cancer-type-specific co-occurring mutations distinct gene expression signatures. heterogeneity primary significant, affecting allele frequency, which could lead unpredictable branching development metastases. Selection minute subclones tumors or metastases during target therapies can occur colorectal acquired resistance. Ultrahigh sensitivity techniques now routinely available for diagnostic purposes, but proper determination frequency metastatic tissues may have larger clinical significance.

Language: Английский

---

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

Journal for ImmunoTherapy of Cancer, Journal Year: 2018, Volume and Issue: 6(1)

Published: July 16, 2018

Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung (NSCLC) accounting for over 85% all cases. Until recently, chemotherapy - characterized by some benefit but only rare durable responses was treatment option patients NSCLC whose tumors lacked targetable mutations. By contrast, immune checkpoint inhibitors have demonstrated distinctly and represent advent a new approach NSCLC. Three inhibitors, pembrolizumab, nivolumab atezolizumab, are now approved use in first- and/or second-line settings selected advanced NSCLC, promising also seen stage III Additionally, durvalumab following chemoradiation has been locally disease. Due to distinct features immunotherapy, rapid progress field, clinical guidance needed on these agents, including appropriate patient selection, sequencing therapies, response monitoring, adverse event management, biomarker testing. The Society Immunotherapy Cancer (SITC) convened an expert Task Force charged developing consensus recommendations key issues. Following systematic process as outlined National Academy Medicine, literature search panel voting were used rate strength evidence each recommendation. This statement provides evidence-based help clinicians integrate into plan will be updated relevant advances field.

Language: Английский

---

The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA

Biochemical and Biophysical Research Communications, Journal Year: 2019, Volume and Issue: 512(3), P. 479 - 485

Published: March 21, 2019

Language: Английский

---

DLL3: an emerging target in small cell lung cancer

Journal of Hematology & Oncology, Journal Year: 2019, Volume and Issue: 12(1)

Published: June 18, 2019

Small cell lung cancer (SCLC) accounts for approximately 15% of all cancers. Despite high rates response to first-line chemotherapy and radiotherapy, patients with extensive-stage disease eventually relapse, very few survive more than 5 years from diagnosis. Treatment options recurrent or refractory are limited, the treatments that do exist associated significant treatment-related toxicities. Delta-like ligand 3 (DLL3) is an inhibitory Notch highly expressed in SCLC other neuroendocrine tumors but minimally normal tissues. It therefore being explored as a potential therapeutic target SCLC. Here, we review preclinical clinical evidence targeting DLL3 discuss several DLL3-specific therapies developed treatment SCLC: antibody-drug conjugate rovalpituzumab tesirine, bispecific T engager immuno-oncology therapy AMG 757, chimeric antigen receptor 119.

Language: Английский

---

Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review)

International Journal of Molecular Medicine, Journal Year: 2018, Volume and Issue: unknown

Published: May 17, 2018

β‑catenin/CTNNB1 is an intracellular scaffold protein that interacts with adhesion molecules (E‑cadherin/CDH1, N‑cadherin/CDH2, VE‑cadherin/CDH5 and α‑catenins), transmembrane‑type mucins (MUC1/CD227 MUC16/CA125), signaling regulators (APC, AXIN1, AXIN2 NHERF1/EBP50) epigenetic or transcriptional (BCL9, BCL9L, CREBBP/CBP, EP300/p300, FOXM1, MED12, SMARCA4/BRG1 TCF/LEF). Gain‑of‑function CTTNB1 mutations are detected in bladder cancer, colorectal gastric liver lung pancreatic prostate cancer uterine whereas loss‑of‑function CTNNB1 also human cancer. ABCB1, ALDH1A1, ASCL2, ATF3, AXIN2, BAMBI, CCND1, CD44, CLDN1, CTLA4, DKK1, EDN1, EOMES, FGF18, FGF20, FZD7, IL10, JAG1, LEF1, LGR5, MITF, MSX1, MYC, NEUROD1, NKD1, NODAL, NOTCH2, NOTUM, NRCAM, OPN, PAX3, PPARD, PTGS2, RNF43, SNAI1, SP5, TCF7, TERT, TNFRSF19, VEGFA ZNRF3 representative β‑catenin target genes. involved myofibroblast activation subsequent pulmonary fibrosis, addition to other types of fibrosis. NF‑κB field cancerization the stomach associated Helicobacter pylori (H. pylori) infection hepatitis C virus (HCV) etiologies. β‑catenin‑targeted therapeutics functionally classified into inhibitors targeting upstream (AZ1366, ETC‑159, G007‑LK, GNF6231, ipafricept, NVP‑TNKS656, rosmantuzumab, vantictumab, WNT‑C59, WNT974 XAV939), protein‑protein interactions (CGP049090, CWP232228, E7386, ICG‑001, LF3 PRI‑724), (PKF118‑310), mediator complexes (CCT251545 cortistatin A) outputs, including CD44v6, FZD7 LGR5. Eradicating H. HCV optimal approach for first‑line prevention hepatocellular carcinoma (HCC), respectively. However, may be applicable organ second‑line HCC treating β‑catenin‑driven The multi‑layered treatment strategy β‑catenin‑related diseases necessary practice personalized medicine implementation precision medicine.

Language: Английский

---